Femto Technologies Secures $17 Million Investment to Advance Feminine Wellness Technology

Femto Technologies Inc., a FemTech pioneer, has secured $17 million through a private placement investment, positioning the company to advance its innovative feminine wellness technologies. The company will issue common shares and warrants to institutional investors at $4.17 per common unit, with the transaction expected to close on February 27, 2025. This substantial funding round represents a significant vote of confidence in the growing FemTech sector and Femto's technological approach to addressing women's health needs.

The investment structure includes the sale of common units comprising common shares, Series A warrants, and Series B PIPE common warrants. Series A warrants will have an initial exercise price of $5.21 per common share and expire 60 months after issuance, while Series B warrants will have an initial exercise price of $12.51 per common share and expire 30 months after issuance. This complex financial arrangement demonstrates the sophisticated nature of the investment and the long-term commitment from institutional backers to Femto's vision and growth trajectory in the feminine wellness market.

Femto plans to utilize the net proceeds from the offering for general corporate purposes and working capital. The funding will specifically support further development of Sensera, the company's flagship feminine wellness device that integrates proprietary Smart Release System technology featuring machine learning and artificial intelligence. This technological foundation represents a significant advancement in how feminine wellness products can adapt to individual user needs through sophisticated algorithms and data analysis.

The Sensera device recently received a CES Innovation Awards 2025 Honorary designation in the AI category, highlighting the recognition Femto's technology has earned within the broader technology community. This award designation from one of the technology industry's most prestigious showcases validates Femto's approach to bridging gaps in feminine wellness through advanced technological solutions. The device is engineered to provide a holistic self-care experience that dynamically adapts to women's changing physiological needs throughout different life stages and circumstances.

Aegis Capital Corp. is serving as the exclusive placement agent for this private placement transaction. The securities are being offered solely to accredited investors in a private transaction not involving a public offering, and have not been registered under the Securities Act of 1933. This financial milestone underscores Femto Technologies' strategic positioning in the emerging FemTech market, signaling continued innovation and potential growth in female wellness technologies that combine cutting-edge artificial intelligence with intimate health care solutions.